My Sanford Chart allows you secure online access to your personal health information and your child's health information. It's available anywhere you have internet access. There is no cost to you and registering is quick and simple.

Sign Up for My Sanford Chart
Study ID: ECOG E1512

A Randomized Phase II Trial of Erlotinib, Cabozantinib, or Erlotinib plus Cabozantinib as 2nd or 3rd Line Therapy in Patients with EGFR Wild-Type NSCLC


The purpose of this study is to compare the progression-free survival (PFS) associated with patients treated with erlotinib vs. erlotinib plus cabozantinib. Participants in this study have been diagnosed with EGFR wild-type non-small cell lung cancer (NSCLC). In addition this study will also compare the PFS associated with participants treated with erlotinib vs. cabozantinib.

Bemidji Clinic, Fargo Region, Sioux Falls Region
Principal Investigator:
Miroslaw Mazurczak MD,Preston Steen, MD,Preston Steen, MD
Non-Small Cell Lung Cancer
Phase II


Active - Open to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.

Back to Clinical Trials list